Header Logo

Connection

AYSEGUL A SAHIN to Prognosis

Back to Details
This is a "connection" page, showing publications AYSEGUL A SAHIN has written about Prognosis.
AYSEGUL A SAHIN
Connection Strength
0.681
Prognosis
  1. The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. JAMA Oncol. 2016 Jul 01; 2(7):929-36.
    View in: PubMed
    Score: 0.038
  2. Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Arch Pathol Lab Med. 2015 Oct; 139(10):1288-94.
    View in: PubMed
    Score: 0.035
  3. Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer. 2012 Mar 15; 118(6):1507-14.
    View in: PubMed
    Score: 0.027
  4. Age and associated fibrocystic changes are prognostically significant in patients with small node-negative (T1a,bN0) invasive breast cancer. Breast J. 2011 Sep-Oct; 17(5):462-9.
    View in: PubMed
    Score: 0.027
  5. Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Invest. 2010 Jun; 28(5):554-9.
    View in: PubMed
    Score: 0.025
  6. Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer. Arch Pathol Lab Med. 2009 Jun; 133(6):869-78.
    View in: PubMed
    Score: 0.023
  7. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer. 2009 Apr 15; 115(8):1605-12.
    View in: PubMed
    Score: 0.023
  8. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005 Aug 15; 104(4):676-81.
    View in: PubMed
    Score: 0.018
  9. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma. Clin Breast Cancer. 2024 Jun; 24(4):e310-e318.
    View in: PubMed
    Score: 0.016
  10. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003 Sep 01; 98(5):1055-60.
    View in: PubMed
    Score: 0.016
  11. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod Pathol. 2003 Feb; 16(2):120-9.
    View in: PubMed
    Score: 0.015
  12. Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol. 2022 05; 35(5):601-608.
    View in: PubMed
    Score: 0.014
  13. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.
    View in: PubMed
    Score: 0.014
  14. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol. 2000 May; 7(3):158-66.
    View in: PubMed
    Score: 0.013
  15. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett. 2019 11 28; 465:12-23.
    View in: PubMed
    Score: 0.012
  16. Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. Ann Surg Oncol. 2019 Jun; 26(6):1720-1728.
    View in: PubMed
    Score: 0.012
  17. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.011
  18. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):568-577.
    View in: PubMed
    Score: 0.011
  19. Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer. 2018 10; 18(5):347-352.
    View in: PubMed
    Score: 0.011
  20. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat. 2017 Dec; 166(3):743-755.
    View in: PubMed
    Score: 0.010
  21. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2017 01; 161(2):279-287.
    View in: PubMed
    Score: 0.010
  22. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002.
    View in: PubMed
    Score: 0.010
  23. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
    View in: PubMed
    Score: 0.010
  24. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8.
    View in: PubMed
    Score: 0.009
  25. Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer. J Clin Oncol. 2015 Apr 01; 33(10):1119-27.
    View in: PubMed
    Score: 0.009
  26. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417.
    View in: PubMed
    Score: 0.008
  27. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat. 2014 Jan; 143(1):189-201.
    View in: PubMed
    Score: 0.008
  28. Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5.
    View in: PubMed
    Score: 0.008
  29. DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-?-driven epithelial-mesenchymal transition. Cancer Discov. 2013 Oct; 3(10):1172-89.
    View in: PubMed
    Score: 0.008
  30. Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(3):917-24.
    View in: PubMed
    Score: 0.008
  31. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.007
  32. Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
    View in: PubMed
    Score: 0.007
  33. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.007
  34. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One. 2011; 6(8):e23543.
    View in: PubMed
    Score: 0.007
  35. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 01; 68(3):549-57.
    View in: PubMed
    Score: 0.007
  36. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
    View in: PubMed
    Score: 0.007
  37. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011 May 20; 29(15):1956-62.
    View in: PubMed
    Score: 0.007
  38. Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer. 2011 Apr; 2(2):132-43.
    View in: PubMed
    Score: 0.007
  39. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77.
    View in: PubMed
    Score: 0.007
  40. Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer. Cancer. 2011 Apr 15; 117(8):1595-601.
    View in: PubMed
    Score: 0.006
  41. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010 Oct; 177(4):1647-56.
    View in: PubMed
    Score: 0.006
  42. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010 Aug 01; 77(5):1296-302.
    View in: PubMed
    Score: 0.006
  43. Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer. 2010 Feb; 1(1):21-33.
    View in: PubMed
    Score: 0.006
  44. Flow cytometric analysis of the DNA content of non-small cell lung cancer. Ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung. Cancer. 1990 Feb 01; 65(3):530-7.
    View in: PubMed
    Score: 0.006
  45. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.
    View in: PubMed
    Score: 0.006
  46. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009 Jun 01; 15(11):3654-62.
    View in: PubMed
    Score: 0.006
  47. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068.
    View in: PubMed
    Score: 0.006
  48. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.006
  49. Staging of breast cancer in the neoadjuvant setting. Cancer Res. 2008 Aug 15; 68(16):6477-81.
    View in: PubMed
    Score: 0.006
  50. Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res. 2008; 10(4):212.
    View in: PubMed
    Score: 0.006
  51. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol. 2008 Jan 10; 26(2):246-52.
    View in: PubMed
    Score: 0.005
  52. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
    View in: PubMed
    Score: 0.005
  53. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
    View in: PubMed
    Score: 0.005
  54. Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat. 2006 Aug; 98(3):295-301.
    View in: PubMed
    Score: 0.005
  55. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11.
    View in: PubMed
    Score: 0.005
  56. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005 Sep; 18(9):1165-75.
    View in: PubMed
    Score: 0.005
  57. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. Cancer. 2005 Jul 15; 104(2):229-35.
    View in: PubMed
    Score: 0.004
  58. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
    View in: PubMed
    Score: 0.004
  59. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005 May 01; 11(9):3309-14.
    View in: PubMed
    Score: 0.004
  60. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005 May 01; 11(9):3315-9.
    View in: PubMed
    Score: 0.004
  61. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
    View in: PubMed
    Score: 0.004
  62. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis. 2005; 22(1):39-46.
    View in: PubMed
    Score: 0.004
  63. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004 Feb 01; 100(3):499-506.
    View in: PubMed
    Score: 0.004
  64. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer. 2004 Jan 01; 100(1):12-9.
    View in: PubMed
    Score: 0.004
  65. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol. 2002 Oct; 12(4):319-28.
    View in: PubMed
    Score: 0.004
  66. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002 Jan; 194(1):54-64.
    View in: PubMed
    Score: 0.004
  67. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12.
    View in: PubMed
    Score: 0.003
  68. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001 May 15; 91(10):1845-53.
    View in: PubMed
    Score: 0.003
  69. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8.
    View in: PubMed
    Score: 0.003
  70. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer. 1997 Dec 15; 80(12):2240-9.
    View in: PubMed
    Score: 0.003
  71. Analysis of telomerase activity levels in breast cancer: positive detection at the in situ breast carcinoma stage. Clin Cancer Res. 1997 Jan; 3(1):11-6.
    View in: PubMed
    Score: 0.002
  72. Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg. 1996 Mar; 223(3):342-7.
    View in: PubMed
    Score: 0.002
  73. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 1992 Aug 19; 84(16):1256-61.
    View in: PubMed
    Score: 0.002
  74. Thymoma. The prognostic significance of flow cytometric DNA analysis. Cancer. 1992 Apr 01; 69(7):1702-9.
    View in: PubMed
    Score: 0.002
  75. Prognostic factors in esophageal squamous carcinoma. A study of histologic features, blood group expression, and DNA ploidy. Am J Clin Pathol. 1991 Jun; 95(6):844-9.
    View in: PubMed
    Score: 0.002
  76. Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. N Engl J Med. 1991 Apr 18; 324(16):1084-90.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.